Sheet Mask Safety Documentation: How Canadian Cosmetic Rules Compare With MoCRA for the Same Treatment Room

One mask, two rulebooks: cosmetic documentation in Canada and under MoCRA

The same sheet mask can be sold to a clinic in Toronto and to a clinic in Buffalo, from one factory, under two sets of paperwork that are not translations of each other. The American side now has a named party who must hold evidence that the product is safe. The Canadian side has no equivalent pre-market file: the duty is expressed as a prohibition on selling a product that may injure, plus a narrower rule that attaches evidence to claims. Buyers who assume the two systems are the same end up asking Canadian suppliers for a document that does not exist there, and American suppliers for a language of label that their carton does not carry.

That mismatch is not a defect in either system; it is a difference in regulatory design. One regulates by requiring a file, the other by prohibiting outcomes and by putting the evidential burden on claims. For a clinic, the practical question is not which system is stricter. It is which document, held by which party, answers the question a provider or an inspector is actually asking — and whether the same paperwork can serve both. Take one product and follow it across: the post-procedure hydrating sheet mask is a cosmetic in both markets, and the two files that sit behind it are not translations of each other.

Which obligations differ, line by line?

Six lines do most of the work. They are set out below with the instrument that carries each one, because the citation is what lets a buyer check the answer instead of trusting a summary. The rows are deliberately parallel: the same six questions, asked of both systems.

Six questions, two instruments. The Canadian column is a prohibition plus a claim rule; the American column is a filing plus a file
Question United States (MoCRA) Canada (Food and Drugs Act and Cosmetic Regulations)
Who is accountable? A named responsible person, with a US address and phone on the label The manufacturer and the importer; the label has to carry a contact route at (s.20)
Is there a pre-market step? Facility registration and product listing, plus safety substantiation held before sale No pre-market safety filing; the prohibition in section 16 of the Act applies at the point of sale
What evidence is required? Adequate substantiation of safety for the product as labelled, held as records Evidence that validates a claim, where a claim is made about skin, hair or teeth chemistry or about formulation or performance (s.21)
Do claims change the obligation? Yes: a claim that treats or prevents disease moves the product to the drug side Yes: a claim covered by s.21 needs evidence, and the manufacturer must give it to the Minister on request
What does the label have to carry? The responsible person, and the information the applicable rules prescribe Prescribed information in both English and French, except INCI names (s.18), plus identity and contact details (s.20)
What happens on a reaction? Serious adverse events are reported by the responsible person, and the record is kept The sale prohibition and the claim rule do the work; record-keeping is driven by the label and claims obligations

Read across row three and the practical difference appears. In the United States the duty exists whether or not anybody makes a claim. In Canada the general prohibition applies to every sale, but the specific evidential burden is attached to claims — which means a Canadian supplier can lawfully have no dossier at all, provided the product is not injurious and nothing on the label or in the advertising trips section 21.

What does the Canadian claim rule actually cover?

Two categories, and both are worth reading carefully. The first is a claim about the ability of the cosmetic or any of its ingredients to influence the chemistry of the skin, hair or teeth. The second is a claim about the formulation, manufacture or performance that would imply the user will not suffer injury to health. In either case the manufacturer may not make the claim unless it has evidence that validates it, and must provide that evidence to the Minister on request.

Notice who the duty sits on: the manufacturer, not the clinic and not the distributor. Notice also that it is a duty about claims, so the first thing to read is the marketing copy. A hydrating mask described as improving the appearance of dry skin is one conversation; the same product described as repairing a barrier after a procedure is a stronger claim and drags the evidence question with it. That is why the artwork belongs in the file on both sides of the border, for different reasons: in Canada it defines whether section 21 is engaged at all, and in the United States it defines what the substantiation has to cover. Our post-procedure hydrating sheet mask page states the use conditions for exactly that reason.

Diagram, not a photograph: three columns comparing the United States, Canada and the overlap for sheet mask documentation. Six questions run down each system column covering accountability, pre-market steps, evidence, claims, label content and reaction handling, and the third column marks which items are shared between the two systems and which are not.
Six rows, two systems. The third column is where a single document set can be reused.

Why does bilingual labelling change the artwork and not the formula?

Because it is a labelling obligation, not a product obligation. The Cosmetic Regulations require that information the regulations require to appear on the label be shown in both English and French, with the INCI name excepted, and be legible throughout the useful life of the product. The inner label must also carry a contact route for consumer questions and the identity of the product, unless the identity is obvious.

Three consequences follow for anyone buying on both sides of the border. First, a US carton is not a Canadian carton: the same formula needs a second artwork. Second, the INCI exception means the ingredient list is the one block that does not need translating, which is why ingredient blocks usually survive a market transfer unchanged while directions and warnings do not. Third, “legible throughout the useful life” rules out the cheap route of a sticker over a US panel: a sticker that lifts in a wet treatment room fails a requirement that the underlying carton never had to meet.

Six label elements and what happens to each when one SKU serves two markets
Element US carton Canadian carton What it means for a shared SKU
Product identity As labelled Required on the inner label unless obvious Keep identity wording identical so the same carton blank can be used
Contact details Responsible person, US contact A route for consumer questions Two different blocks; both fit on one back panel
Language English English and French, except INCI Second artwork, same formula
Ingredient list As labelled INCI, exempt from translation Reusable as-is
Directions and warnings As labelled Both languages Translate, do not sticker
Durability As labelled Legible for the useful life Rules out thin over-labels

Where can one document set serve both markets?

Three places, and they are the three that cost the most to produce. The ingredient composition is shared: both systems describe the product by what is in it, and the INCI block is the one part of the label Canada does not require translated. The manufacturing description is shared: a site that can describe its process and its controls in a form an auditor accepts is doing the same work for either market. And the claim wording should be shared, because divergent claims create two evidence problems out of one product.

What cannot be shared is the framing. A Canadian file organised as “here is the evidence for each claim” and an American file organised as “here is the substantiation for the product as labelled” answer different questions, and copying one into the other leaves a visible gap. The workable arrangement is a shared core with two thin covers: one cover that names the US responsible person and the listing, one that maps each claim to the evidence that validates it.

What should a clinic actually keep on the shelf?

Four items, in one folder per product. The label as printed, in the language of the market it was sold in, because the label is what defines the use conditions on both sides. The name and contact route of the party accountable in that market — the responsible person for a US sale, the manufacturer or importer for a Canadian one. The claim list, matched to whichever evidence statement the supplier will put in writing. And the lot code convention, so a reaction report can be tied to a batch.

Nothing on that list requires the clinic to hold a factory’s test report, and no supplier should be asked for one. The clinic’s job is to be able to answer, in one page, which product, which label, which claim, which lot, and who was accountable. Rooms that run both a professional mask and a procedure mask should keep the two regimes apart: the ASTM F2100 level 2 procedure mask is protective equipment, not a cosmetic, and the questions that apply to it are filtration and fit rather than substantiation.

Diagram, not a photograph: four cards on what a clinic keeps per product across two markets. The first is the label as printed in the market it was sold in, the second is the accountable party for that market, the third is the claim list matched to evidence, and the fourth is the lot code convention.
Four items per product per market. The rest of the file belongs to the manufacturer.

Primary sources. Canadian provisions were read in the consolidated Justice Laws text current at the date of writing; the American provisions are cited so that the comparison can be checked rather than taken from this page.

Where does this go next?

Three things here are usable rather than readable. The printable compliance log holds the fields a receiving check, a lot trace and a reprocessing record actually need, so the paperwork can start without inventing a format. The clinic supply planner turns monthly treatment volume into a mask order and shows which format keeps the reorder point in cases rather than units. The product safety hub collects the rest of the guides for this setting. Multi-site or purchasing-group enquiries go through the wholesale account route, where case quantities and delivery frequency are set once rather than per order.

Questions that go past a template — a record format an inspector asked for, or a retention period your college is challenging — belong with the compliance consultation desk rather than a generic contact form.

Related reading

Frequently Asked Questions

Does Canada require a pre-market safety file for a cosmetic?

No. The Canadian instrument works by prohibiting the sale of a cosmetic that may injure health, is filthy or decomposed, or was made or stored under unsanitary conditions, and by separately requiring evidence for the kind of claims covered by section 21 of the Cosmetic Regulations.

Is the American safety substantiation record the same document as a Canadian claim file?

No, and they cannot be swapped. The American record substantiates the safety of the product as labelled; the Canadian duty is to hold evidence that validates a specific claim when the claim is made. They overlap in the core data and differ in what they are answering.

Which label element is exempt from the French requirement?

The INCI name. Everything else the regulations require on the label has to appear in both official languages, and it has to stay legible for the useful life of the product, which is why an over-sticker on a US carton is a poor substitute for a second artwork.

Who is accountable in each market?

In the United States, the named responsible person with a US address and contact details. In Canada, the manufacturer for the claim duty and the label contact route for the consumer question. A clinic should be able to name the accountable party on each side in one line.

Do claims really change the paperwork?

They change which question the paperwork has to answer. In Canada a claim covered by section 21 creates the evidential duty; in the United States a claim that treats or prevents a condition can move the product into the drug category, with a different evidence standard entirely.

What should a clinic ask a supplier that sells into both countries?

For the label as printed in each market, the accountable party in each market, the claim list, and the lot code convention. Asking for a single certificate that covers both markets is asking for a document that does not exist.

CliniEco Medical holds Health Canada MDEL #35334. Statutory and regulatory references are to the instruments named in the source list; a clinic should confirm the current text and its own obligations with the body that publishes them. This page is general information about documentation, cataloguing and record-keeping, not clinical or legal advice. Confirm the current specification, part number and order status on the product page, and confirm the current wording of any regulation with the body that publishes it. MDEL #35334 identifies our establishment licence; it is not a statement about any individual product.

Vous travaillez déjà avec des cliniques ? Devenez représentant régional.